Stacey Schaeffer, M.A. Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 5284 Paylor Ln, Lakewood Ranch, FL 34240 Phone: 941-704-5200 |
Maritza Garza, M.A., L.M.F.T. Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 9080 58th Dr E, 200b, Lakewood Ranch, FL 34202 Phone: 805-201-8406 |
Mrs. Carley Rowe Sullivan, MA Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 9015 Town Center Pkwy Ste 138, Lakewood Ranch, FL 34202 Phone: 757-797-6006 |
Mintha Sheffield Esformes, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 7207 Teal Creek Gln, Lakewood Ranch, FL 34202 Phone: 520-818-4934 |
Mrs. Chima Hope-lubin, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 9015 Town Center Pkwy Unit 111, Lakewood Ranch, FL 34202 Phone: 941-725-9732 |
News Archive
Successful supply chain management, including managing demand, planning API and formulation production, packaging and distributing, is a goal shared by all pharmaceutical manufacturers. According to PharmaTech.com, effective supply-chain management is particularly important as the pharmaceutical industry seeks ways to reduce costs, maintain regulatory compliance, and adhere to quality and safety standards.
The School of Medicine at the University of California, Riverside has been awarded a grant of $3 million over a two-year period from health care provider Kaiser Permanente Southern California to increase the size and reach of the school's existing "pipeline programs" - a continuum of student enrichment and academic support programs - and thus broaden and diversify the pool of students applying to medical school.
Cascade Chemistry, a leading contract research and manufacturing organization serving the pharmaceutical, materials, and chemical industries, today announced that it has been selected to produce the active pharmaceutical ingredient for clinical trial supplies of RBT-9, an investigational therapy entering a Phase 2 trial for the treatment of COVID-19 patients who are at high risk of deteriorating health due to age or comorbid conditions such as kidney or cardiovascular disease.
"Premiums that seniors pay for Medicare Advantage plans will increase an average of 25% next year, largely because insurers, in response to new federal requirements, are canceling many plans that carry no premiums, a top Medicare official said Wednesday," The Wall Street Journal reports.
› Verified 7 days ago